Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perﬂuorocarbon

Wu, pingping; Zhou, Qing; Zhu, Huayun; Zhou, Yan; Bao, Jie

doi:10.21203/rs.2.17524/v4

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another recent study reported targeted delivery of 5-fluorouracil (5Fu) and perfluorocarbon for effective treatment of colon cancer through epidermal growth factor-(EGF-) functionalized PLGA NPs. The functionalized NPs were capable of selective localization of both the drugs into colon cancer cells and inhibited tumor growth through their ability of recognizing specific receptors present on colon cancer cells [117].…”

Section: Targeting Colon Cancermentioning

confidence: 99%

Recent Trends in Nanocarrier-Based Targeted Chemotherapy: Selective Delivery of Anticancer Drugs for Effective Lung, Colon, Cervical, and Breast Cancer Treatment

Jin

Chen³

et al. 2020

Journal of Nanomaterials

View full text Add to dashboard Cite

Chemotherapy drugs are cytotoxic to tumor cells, but their lack of specificity leads to a range of side effects. The off-target effects of such drugs can be improved through the use of nanoparticles (NPs). Administered NPs show enhanced accumulation in tumor tissue near the blood vessels, enhancing both anticancer drug permeability and tumor retention. Several nanocarriers are now approved for clinical use in a range of cancer therapies, and many novel formulations are in the later stages of clinical trials. Here, we describe the advances in this area through the review of novel NP drug formulations developed over the last year. We focus specifically on lung, colon, cervical, and breast cancers and discuss the future of NPs as potential treatment options in these areas.

show abstract

Section: Targeting Colon Cancermentioning

confidence: 99%

Recent Trends in Nanocarrier-Based Targeted Chemotherapy: Selective Delivery of Anticancer Drugs for Effective Lung, Colon, Cervical, and Breast Cancer Treatment

Jin

Chen³

et al. 2020

Journal of Nanomaterials

View full text Add to dashboard Cite

show abstract

“…5fluorouracil , an antimetabolite analogue of pyrimidine, inhibits nucleoside metabolism and DNA synthesis, leading to apoptosis [5]. Several studies have focussed on the development of effective vectors to improve the targeted delivery of 5-Fu; attempts have been made to increase the bioavailability of 5-Fu and decrease its toxicity in vivo by administering lower doses and ensuring the optimum accumulation of the drug at the affected site [6][7][8][9]. Despite these advances, drug resistance remains a major limitation to the clinical use of 5-Fu.…”

Section: Introductionmentioning

confidence: 99%

Identification and validation of a seven‐gene prognostic marker in colon cancer based on single‐cell transcriptome analysis

Zhou

Yang²,

Wang

2022

IET Systems Biology

View full text Add to dashboard Cite

Colon cancer (CC) is one of the most commonly diagnosed tumours worldwide. Single‐cell RNA sequencing (scRNA‐seq) can accurately reflect the heterogeneity within and between tumour cells and identify important genes associated with cancer development and growth. In this study, scRNA‐seq was used to identify reliable prognostic biomarkers in CC. ScRNA‐seq data of CC before and after 5‐fluorouracil treatment were first downloaded from the Gene Expression Omnibus database. The data were pre‐processed, and dimensionality reduction was performed using principal component analysis and t‐distributed stochastic neighbour embedding algorithms. Additionally, the transcriptome data, somatic variant data, and clinical reports of patients with CC were obtained from The Cancer Genome Atlas database. Seven key genes were identified using Cox regression analysis and the least absolute shrinkage and selection operator method to establish signatures associated with CC prognoses. The identified signatures were validated on independent datasets, and somatic mutations and potential oncogenic pathways were further explored. Based on these features, gene signatures, and other clinical variables, a more effective predictive model nomogram for patients with CC was constructed, and a decision curve analysis was performed to assess the utility of the nomogram. A prognostic signature consisting of seven prognostic‐related genes, including CAV2 , EREG , NGFRAP1 , WBSCR22 , SPINT2 , CCDC28A , and BCL10 , was constructed and validated. The proficiency and credibility of the signature were verified in both internal and external datasets, and the results showed that the seven‐gene signature could effectively predict the prognosis of patients with CC under various clinical conditions. A nomogram was then constructed based on features such as the RiskScore, patients' age, neoplasm stage, and tumor (T), nodes (N), and metastases (M) classification, and the nomogram had good clinical utility. Higher RiskScores were associated with a higher tumour mutational burden, which was confirmed to be a prognostic risk factor. Gene set enrichment analysis showed that high‐score groups were enriched in ‘cytoplasmic DNA sensing’, ‘Extracellular matrix receptor interactions’, and ‘focal adhesion’, and low‐score groups were enriched in ‘natural killer cell‐mediated cytotoxicity’, and ‘T‐cell receptor signalling pathways’, among other pathways. A robust seven‐gene marker for CC was identified based on scRNA‐seq data and was validated in multiple independent cohort studies. These findings provide a new potential marker to predict the prognosis of patients with CC.

show abstract

“…Selenium NPs, poly (lactic-co-glycolic) acid NPs with inorganic molybdenum octahedral cluster, Fe 2 O 3 NPs, PEGL NPs, chitosan copolymermagnetic NPs, poly-ε-caprolactone NPs Inhibition of cancer cell growth, cytotoxic effect on cancer cells, reduction of metastasis, decrease of cancer cell viability and cytotoxicity, increased the intracellular ROS/RNS, diminution of tumor volume[194][195][196][197][198][199] Colon cancer Albumin NPs, chitosan NPs, perfluorooctylbromide-porphyrin grafted lipid NPs, biosynthesized silver NPs, superparamagnetic iron oxide coated with mesenchymal stem cell, silver and gold NPs, mesoporous silica NPs coated with folic acid chitosan-glycine complex, hydroxyapatite NPs coated with gum Arabic, PLGA NPs co-loaded with 5-fluorouracil and perfluorocarbonEnhancement of cancer cells killing; improved antitumor efficacy; prevention of tumor growth and metastasis; decrement of tumor volume; enhancement of photodynamic effects against cancer cells (by increasing oxidative stress); induction of apoptosis (overexpression of caspase-3, caspase-9, bid, and Bax); reduction of immune system response and systemic side effects; fragmentation of DNA in cancer cells; increase in antimitotic effects[200][201][202][203][204][205][206][207] Glioblastoma Silver NPs, lanthanum oxide NPs, transferrinconjugated porous silicon NPs, high-Z metal NPs, PEI surface-functionalized mesoporous silica NPs, PLGA NPs coated with polyvinyl alcohol and Poloxamer188, magnetic iron oxide NPs loaded trimethoxysilylpropyl-ethylenediamine triacetic acid, polymerized human serum albumin NPs, PEI-PEG-magnetic iron oxide NPs…”

mentioning

confidence: 99%

Combining Nanotechnology and Gas Plasma as an Emerging Platform for Cancer Therapy: Mechanism and Therapeutic Implication

Rasouli

Fallah

Bekeschus

2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Nanomedicine and plasma medicine are innovative and multidisciplinary research fields aiming to employ nanotechnology and gas plasma to improve health-related treatments. Especially cancer treatment has been in the focus of both approaches because clinical response rates with traditional methods that remain improvable for many types of tumor entities. Here, we discuss the recent progress of nanotechnology and gas plasma independently as well as in the concomitant modality of nanoplasma as multimodal platforms with unique capabilities for addressing various therapeutic issues in oncological research. The main features, delivery vehicles, and nexus between reactivity and therapeutic outcomes of nanoparticles and the processes, efficacy, and mechanisms of gas plasma are examined. Especially that the unique feature of gas plasma technology, the local and temporally controlled deposition of a plethora of reactive oxygen, and nitrogen species released simultaneously might be a suitable additive treatment to the use of systemic nanotechnology therapy approaches. Finally, we focus on the convergence of plasma and nanotechnology to provide a suitable strategy that may lead to the required therapeutic outcomes.

show abstract

Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perﬂuorocarbon

Cited by 3 publications

References 23 publications

Recent Trends in Nanocarrier-Based Targeted Chemotherapy: Selective Delivery of Anticancer Drugs for Effective Lung, Colon, Cervical, and Breast Cancer Treatment

Recent Trends in Nanocarrier-Based Targeted Chemotherapy: Selective Delivery of Anticancer Drugs for Effective Lung, Colon, Cervical, and Breast Cancer Treatment

Identification and validation of a seven‐gene prognostic marker in colon cancer based on single‐cell transcriptome analysis

Combining Nanotechnology and Gas Plasma as an Emerging Platform for Cancer Therapy: Mechanism and Therapeutic Implication

Contact Info

Product

Resources

About